Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Oct 21, 2023 10:45pm
158 Views
Post# 35695050

RE:RE:RE:RE:RE:RE:New Press Release - Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares

RE:RE:RE:RE:RE:RE:New Press Release - Sirona Biochem Announces Payment of Convertible Debenture Interests in SharesNot exactly but we need to watch this space moving forward.

How many times have we seen 1. Dead silence which results in a steady slide as we all start to wonder, then 2. Crappy financials, then 3. Private placement at crappy prices, then 3-6 months later all of sudden fantastic news that doubled, tripled or quadrupled the stock? Look at the historical low points then look what happens 12 months later. 

Deals and developments take a long time to get underway. When was the last time they told us they were in possession of a term sheet or even the types of business development activities underway that was not talking about ideas and strategies on a fancy PowerPoint but actual concrete actions? Textbook MBA strategy is like a holding a wet noodle. There had to be a term sheet for 1067 with AbbVie that came early on but did we know? No. Even disclosure of an anonymous term sheet would have been helpful. Let me guess, the term sheet said everyone had to be secret squirrel. Yeah yeah...secret squirrel.
 
I believe they are extraordinarily poor communicators and don't know how, or even care, to communicate the science or business development in a way that an everyday investor would understand and lead to driving a fair market valuation. 

Where was the fall update? If Michelle was still there, we probably would know what is going on with 1. Anti-viral; 2. What is happening with Anti-aging follow up to their big event where they met with "strong interest" and Howard was strutting down the hallway like a lone Peacock proud of his meetings with big pharma, and 3. What can they say which would reaffirm the 1067 launch partner committment. With a little bit of reassurance we probably would be still at 13 cents and not 9 cents - not much for what we are all looking for but it would have made a difference here on the interest conversion.

How about they get off their arzes and add a few independent board members to start.

IMHO
 
There are a few scientific minded posters here, but few that can match science with business, and 99.9% of investors don't really know, for better or worse, the value of the science.
<< Previous
Bullboard Posts
Next >>